521323-11-5

Basic information

• Product Name: 2H-Cyclopenta[b]furan-2-one,hexahydro-5-hydroxy-4-(hydroxymethyl)-
• Synonyms: 2H-Cyclopenta[b]furan-2-one,hexahydro-5-hydroxy-4-(hydroxymethyl)-;5-hydroxy-4-(hydroxymethyl)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-one;5-Hydroxy-4-(hydroxymethyl)hexahydro-2H-cyclopenta[b]furan-2-one
• CAS NO: 521323-11-5
• Molecular Formula: C8H12O4
• Molecular Weight: 172.17848
• Mol File: 521323-11-5.mol

Chemical Properties

• Boiling Point: 406.6±25.0 °C(Predicted)
• Appearance: /
• Density: 1.365±0.06 g/cm3(Predicted)
• PKA: 14.36±0.40(Predicted)
• CAS DataBase Reference: 2H-Cyclopenta[b]furan-2-one,hexahydro-5-hydroxy-4-(hydroxymethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Cyclopenta[b]furan-2-one,hexahydro-5-hydroxy-4-(hydroxymethyl)-(521323-11-5)
• EPA Substance Registry System: 2H-Cyclopenta[b]furan-2-one,hexahydro-5-hydroxy-4-(hydroxymethyl)-(521323-11-5)

Safety Data

• Hazardous Substances Data: 521323-11-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2H-Cyclopenta[b]furan-2-one,hexahydro-5-hydroxy-4-(hydroxymethyl)is used as a potential compound for the manufacturing of pharmaceuticals due to its gamma butyrolactone structure and hydrophilic properties.
Used in Polymer Industry:
2H-Cyclopenta[b]furan-2-one,hexahydro-5-hydroxy-4-(hydroxymethyl)is used as a potential compound for the manufacturing of polymers due to its gamma butyrolactone structure and hydrophilic properties.

Upstream product

• 51705-34-1 2-oxa-3-oxo-6-syn-hydroxymethyl-7-anti-acetoxy-cis-bicyclo[3,3,0]octane 
• 61218-08-4 2α-(6-carboxy-hex-cis-2-enyl)-3β-hydroxymethyl-4α-(2-tetrahydropyranyloxy)-cyclopentan-1α-ol 

Downstream Products

• 172821-93-1 corey lactone benzoate 

Relevant articles and documents

20-Hydroxy-prostaglandins

The present invention relates to 20-hydroxy prostaglandins of the formula: STR1 wherein A represents a grouping of the formula: STR2 and X represents ethylene or cis-vinylene and Y represents trans-vinylene, or X and Y each represent ethylene, R represents a hydrogen atom or a straight- or branched-chain alkyl group containing from 1 to 12 carbon atoms, R1 , R2, R3, R4 and R5, which may be the same or different, each represent a hydrogen atom or a methyl or ethyl group, and n represents zero or an integer from 1 to 3 inclusive, and cyclodextrin clathrates of such acids and esters and, when R represents a hydrogen atom, the non-toxic salts thereof. These compounds exhibit characteristic prostaglandin activity.

16-Chloro-substituted prostaglandins and derivatives thereof

The present invention relates to compounds of the formula: STR1 wherein A represents a grouping of the formula: STR2 B represents a single bond or a straight- or branched-chain alkylene group containing from 1 to 9 carbon atoms, W represents ethylene or t

Prostaglandin analogues

Prostaglandin analogues of the formula: STR1 wherein X represents oxygen or sulphur, R1 and R2 each represent hydrogen or alkyl of from 1 to 3 carbon atoms, alkenyl of from 2 to 4 carbon atoms or trifluoromethyl, and the double bonds depicted in positions C5 -C6 and C13 -C14 are cis and trans respectively. These compounds are indicated in the treatment of impaired fertility, induction of labor or termination of pregnancy in females.

Prostaglandin analogues

Prostaglandins of the formula: STR1 wherein A represents a grouping of the formula: STR2 X represents ethylene or cis-vinylene, Y represents ethylene or trans-vinylene, R represents a hydrogen atom or a straight- or branched-chain alkyl group containing f

16-Phenoxy and phenylthio prostaglandin derivatives

The present invention relates to compounds of the formula: STR1 wherein A represents a grouping of the formula: STR2 B represents an oxygen or sulphur atom, R1 and R2, which may be the same or different, each represent a hydrogen or halogen atom, a trifluoromethyl group, or a straight- or branched-chain alkyl or alkoxy group containing from 1 to 4 carbon atoms, R represents a group of the formula --COOR3, in which R3 represents a hydrogen atom or a straight- or branched-chain alkyl group containing from 1 to 12 carbon atoms, or a group of the formula --CH2 OR4, in which R4 represents a hydrogen atom or an alkylcarbonyl group containing from 2 to 5 carbon atoms and the double bonds depicted in positions C2 -C3, C5 -C6 and C13 -C14 are trans, cis and trans respectively, the cyclodextrin clathrates thereof and, when R3 in the group --COOR3 represents a hydrogen atom, non-toxic salts thereof. These compounds exhibit characteristics of prostaglandin-like activity.

16-METHYLENE-PROSTAGLANDIN COMPOUNDS

A compound of the formula: STR1 wherein A represents a grouping of the formula: STR2 , R1 represents a hydrogen atom or a straight- or branched-chain alkyl group containing from 1 to 6 carbon atoms, R2 represents a hydrogen atom or a straight- or branched-chain alkyl group containing from 1 to 12 carbon atoms, X represents trans-vinylene or ethylene, and the wavy line indicates attachment of the hydroxy radical in α- or β-configuration and cyclodextrin clathrates thereof and, when R2 represents a hydrogen atom, non-toxic salts thereof. These compounds exhibit characteristic prostaglandin activity.

Aldehyde derivatives of prostaglandins

Prostaglandin analogues of the formula:- SPC1 Wherein A represents a PGF or PGE grouping, X represents ethylene or cis-vinylene, Y represents ethylene or transvinylene, R1 represents hydrogen or alkyl of 1 to 4 carbon atoms, R2 represents alkyl of 1 to 10 carbon atoms, or alkyl of 1 to 4 carbon atoms substituted by phenyl or cycloalkyl containing from 5 to 7 carbon atoms, or R2 represents a grouping of the formula:- SPC2 Wherein R3 represents alkylene of 1 to 4 carbon atoms, R4 represents oxygen or sulphur or sulphinyl, and R5 and R6 represent hydrogen, halogen, trifluoromethyl, alkyl of 1 to 3 carbon atoms are new compounds possessing pharmacological properties.

Synergistic composition comprising PGF2α and PGE2

A synergistic composition comprising as active ingredients a PGF2α compound or its cyclodextrin clathrate thereof and a PGE2 compound or its cyclodextrin clathrate thereof, at a weight ratio of from about 1:0.33 to about 1:1.